ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1358	National Cancer Institute	Html	en	Gastrointestinal Complications (PDQ®)–Health Professional Version	Expert-reviewed information summary about constipation, impaction, bowel obstruction, and diarrhea as complications of cancer or its treatment. The management of these problems is discussed.	complete bowel obstruction 0.653864 stool 0.625324 gastrointestinal tract 0.642496 Oncol Nurs Forum 0.609323 cancer-related diarrhea 0.733825 refractory diarrhea 0.683452 diarrhea management 0.729396 total bowel rest 0.605453 diarrhea events 0.682702 bone marrow transplantation 0.599048 PUBMED Abstract 0.628255 octreotide acetate 0.600127 bowel lumen 0.596911 abdominal pain 0.618725 progressive bowel obstruction 0.651874 normal bowel function 0.623449 bowel obstruction 0.807553 Support Care Cancer 0.590223 acute diarrhea 0.731833 traveler’s diarrhea 0.692746 regimen-related diarrhea 0.681582 small bowel 0.642547 somatostatin analog octreotide 0.636325 depot octreotide 0.600959	chemotherapy-induced diarrhea 0.813859 malignant bowel obstruction 0.739577 cancer care 0.622581 cancer treatment-induced diarrhea 0.733195 severe diarrhea 0.723383 irritable bowel syndrome 0.602845 patients 0.752157 Clin Oncol 0.637052 cancer patients 0.616135 radiation-induced diarrhea 0.788656 neurogenic bowel dysfunction 0.61585 diarrhea 0.944656 inflammatory bowel disease 0.603068 bone marrow 0.600992 gastrostomy tube 0.601159 Nutr Clin Pract 0.61137 pelvic radiation-induced diarrhea 0.726181 octreotide 0.694845 extraluminal bowel lesions 0.625405 Delayed diarrhea 0.692341 fecal impaction 0.682249 et al. 0.624888 Subcutaneous octreotide 0.602593	CLICK HERE
1593	National Cancer Institute	Html	en	Mistletoe Extracts (PDQ®)–Health Professional Version	Mistletoe, a semiparasitic plant that grows on several types of trees such as apple, oak, pine and elm, is commonly used in cancer patients in Europe. Read about laboratory and human studies of extracts, such as Iscador and Eurixor, and their effects on quality of life, survival and symptom relief in this expert-reviewed summary.	aqueous mistletoe extract 0.442009 mistletoe lectin-1-standardized extract 0.441439 mistletoe extracts 0.647935 recombinant mistletoe lectin 0.458451 Viscum album var. 0.395649 viscum album 0.915234 viscum album extracts 0.415076 Viscum album L. 0.758622 mistletoe preparations 0.534599 orally administered mistletoe 0.439154 breast cancer patients 0.419485 galactoside-specific mistletoe lectin 0.506693 patients 0.47671 cancer patients 0.474171 mistletoe 0.798357 lectin standardized mistletoe 0.506505 galactoside-specific lectin 0.442636 galactoside-binding mistletoe lectin 0.510133 adjuvant mistletoe treatment 0.475546 mistletoe lectin-induced apoptosis 0.437043 mistletoe treatment programme 0.472546 et al. 0.450682 mistletoe lectin ML-1 0.486886 Korean mistletoe lectin 0.477775	mistletoe treatment 0.507798 PUBMED Abstract 0.60337 mistletoe extract 0.555931 Purified mistletoe lectins 0.438108 Viscum album extract 0.453589 different mistletoe preparations 0.423047 Anticancer Res 0.416126 galactoside-specific mistletoe lectin-1 0.433265 mistletoe’s ability 0.439494 blood mononuclear cells 0.426242 standardized mistletoe extracts 0.436989 Gabius HJ 0.430845 European mistletoe 0.545426 mistletoe lectin-II-induced apoptosis 0.4369 breast cancer 0.430552 aqueous mistletoe preparations 0.463767 mistletoe lectins 0.543537 Viscum album preparation 0.39341 unfermented mistletoe preparations 0.438537 iscador 0.417024 mistletoe extract Iscar 0.429817 mistletoe lectin 0.642042 cancer 0.50332 standardized mistletoe extract 0.492996	CLICK HERE
1604	National Cancer Institute	Html	en	Bladder and Other Urothelial Cancers Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for bladder cancer.	red blood cells 0.494369 cancer treatment 0.489394 bladder cancers 0.541229 urine 0.494083 ongoing clinical trials 0.492966 bladder urothelium 0.575205 following PDQ summaries 0.556519 Transitional cell carcinoma 0.483769 PDQ cancer information 0.750577 cancer increases 0.491939 false-negative test result 0.489029 bladder cancer 0.812624 clinical trials 0.684635 test result 0.523443 special test strip 0.489962 cancer information summary 0.626401 clinical trial 0.502183 breast cancer prevention 0.514992 false-positive test result 0.488801 cancer patients 0.484495 latest published information 0.497666 NCI’s PDQ 0.51339 cancer symptoms 0.50531 NCI PDQ cancer 0.589485	tests 0.518118 Squamous cell carcinoma 0.486084 PDQ Screening 0.538371 screening tests 0.491835 Cancer Information Service 0.53331 urothelial cancers 0.536876 PDQ Bladder 0.571685 Prevention Editorial Board 0.549647 treatment clinical trials 0.491831 National Cancer Institute 0.634201 PDQ documents 0.50321 cell carcinoma 0.486793 new treatment 0.498073 Cancer screening trials 0.570719 Cancer Care page 0.519283 PDQ database 0.508182 risk factor 0.512484 PDQ summary 0.54439 cells 0.496479 cancer information summaries 0.541898 comprehensive cancer information 0.541535 renal pelvis 0.488981 cancer 0.961972 Urothelial Cancers Screening 0.519534	CLICK HERE
1723	National Cancer Institute	Html	en	Cell Phones and Cancer Risk	A fact sheet that outlines the available evidence regarding use of cellular/mobile telephones and cancer risk.	study participants 0.44259 Self-reported cell phone 0.407518 past cell phone 0.400866 cell phone calls 0.471967 interphone study 0.417191 cell phone subscribers 0.456865 brain glucose metabolism 0.405692 brain tumors 0.529155 case-control study 0.507596 typical cell phone 0.408953 radiofrequency electromagnetic radiation 0.493663 radiofrequency energy exposure 0.501417 cell phone service 0.411175 radiofrequency energy 0.823507 brain cancer 0.549627 cell phone exposure 0.408273 mobile phone radiation 0.402738 cell phone base 0.419397 mobile phone 0.45428 specific absorption rate 0.399693 GSM mobile phone 0.393442 glucose metabolism 0.4091 Brain cancer incidence 0.408493 brain tumor incidence 0.393633 cell phone user 0.438311	study 0.591826 cohort study 0.434065 United States 0.44975 epidemiologic studies 0.488267 brain tumor risk 0.390841 cell phone 0.960278 cell phone technology 0.436997 National Cancer Institute 0.439672 long-term cell phone 0.404741 cell phones 0.77677 international case-control study 0.404344 prospective cohort study 0.39373 brain tumor 0.434845 brain cancer risk 0.419878 brain 0.559028 regular cell phone 0.406823 non-ionizing radiation 0.395758 cell phone radiofrequency 0.472899 cell phone users 0.536299 cell phone records 0.414439 et al 0.586681 cancer risk 0.424868 cancer 0.54982 risk 0.454009	CLICK HERE
1859	National Cancer Institute	Html	es	Tratamiento del cáncer de hipofaringe (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de hipofaringe.	Neck Cancer Cooperative 0.13741 pharyngeal cancers 0.150792 Pfister DG 0.13468 pyriform sinus treated 0.135606 Cancer Res 0.206838 Radiat Oncol Biol 0.237454 DeVita VT Jr 0.131516 pyriform sinus 0.18629 Natl Cancer Inst 0.207961 radiation therapy 0.254373 Head Neck Surg 0.418544 carcinoma treated with 0.123784 squamous carcinoma 0.207808 with surgery 0.155955 Mendenhall WM 0.309662 Head Neck 0.426668 estadio iv 0.131056 neck squamous 0.149286 Parsons JT 0.126343 radioterapia preoperatoria versus 0.132896 sinus treated with 0.147408 treated with surgery 0.145993 radioterapia posoperatoria 0.168742 Oral Oncol 0.128712 Hendrickson FR 0.131539	treatment based 0.121981 Otolaryngol Head Neck 0.206433 hypopharyngeal carcinomas 0.157978 radiotherapy with 0.12894 with poor prognosis 0.124956 hypopharyngeal squamous 0.152628 Spindle cell carcinoma 0.12283 Clin Oncol 0.138573 combined with neck 0.126143 Oncol Biol Phys 0.243047 combining radiotherapy with 0.126277 estadio iii 0.184936 radiotherapy with surgery 0.128843 Treat Options Oncol 0.123145 radioterapia adyuvante posoperatoria 0.177283 European Organization 0.12179 neck cancer 0.973991 undifferentiated carcinomas 0.126856 quimioterapia neoadyuvante 0.630349 locally advanced 0.131399 Hansen O 0.125257 induction chemotherapy 0.134893 neck carcinoma 0.172184 squamous cell carcinoma 0.867141	CLICK HERE
1887	National Cancer Institute	Html	es	Tratamiento del carcinoma de células de Merkel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del carcinoma de células de Merkel.	Cutan Pathol 0.403221 skin cancer 0.402076 critical review with 0.401107 cell carcinoma showing 0.404318 review with guidelines 0.401112 Australian Merkel cell 0.404544 Distinct merkel cell 0.404503 Am Acad Dermatol 0.404485 cell polyomavirus dna 0.402185 Curr Opin Oncol 0.401201 Cell Carcinoma Information 0.404476 7th ed 0.401399 Rockville Merkel Cell 0.404613 ganglios linfáticos centinela 0.405335 SEER Program 0.402412 cell carcinoma tumors 0.407605 Coit DG 0.402335 into merkel cell 0.405013 Seattle Cancer Care 0.401199 Cancer Care Alliance 0.401228 Natl Cancer Inst 0.40149 Merkel tumours 0.402858 patients with merkel 0.422467 with cutaneous merkel-cell 0.401294 Arch Dermatol 0.401934	cutaneous merkel-cell carcinoma 0.404932 with merkel cell 0.435163 Invest Dermatol 0.401806 neuroendocrine-merkel cell carcinoma 0.404323 Cancer Staging Manual 0.402011 patients from 0.401403 Surg Oncol 0.411261 Nghiem P 0.404669 New York 0.401702 merkel cell carcinoma 0.998942 specimens from patients 0.401221 Clin Oncol 0.41408 Dermatol Surg 0.40166 CCM recién 0.401912 Carcinoma Group 0.402481 cell carcinoma demographics 0.418051 primary merkel 0.405524 Trabecular carcinoma 0.402756 American Joint Committee 0.401365 merkel cell polyomavirus 0.432273 cell carcinoma after 0.40431 cell polyomavirus infection 0.402124 merkel-cell carcinoma 0.40673 from patients with 0.402629	CLICK HERE
1902	National Cancer Institute	Html	es	Tratamiento de los tumores neuroendocrinos de páncreas (tumores de células de los islotes) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores de células de los islotes (páncreas endocrino).	siguientes procedimientos 0.350148 causa dolores 0.307246 siguientes aspectos 0.303943 páncreas causa efectos 0.320993 pequeña cantidad 0.31153 células endocrinas 0.3138 causa debilidad 0.302846 oclusión arterial hepática 0.351832 siguientes tipos 0.303556 vía oral 0.301543 rayos x 0.302476 pequeños electrodos 0.301441 ondas sonoras 0.302366 tumores neuroendocrinos 0.984556 glucagón causa hiperglucemia 0.306311 tne pancreático 0.315238 siguientes riesgos 0.300896 tratamiento quizás 0.303501 endocrina múltiple tipo 0.305298	Instituto Nacional 0.302944 PDQ Tratamiento 0.311878 Colangiopancreatografía retrógrada 0.302587 Medicamentos bloqueadores 0.301556 TNE funcionantes 0.308747 partes distantes 0.304229 siguientes factores 0.304155 Physician Data Query 0.302879 tumores endocrinos 0.310974 causa sensación 0.302849 final angosto 0.303102 siguientes enlaces 0.301371 Alto contenido 0.302594 Ecografía intraoperatoria 0.302362 Baja concentración 0.302446 pancreatectomía distal 0.304071 siguientes pruebas 0.304812 largo tiempo 0.302722	CLICK HERE
1903	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	siguientes procedimientos 0.533869 posibles efectos tardíos 0.429839 células madre 0.925937 posibles factores 0.42224 adultos jóvenes 0.471015 estadio iv 0.456127 Burkitt recién 0.429453 sistema linfático.Para 0.433317 faja ajustadora 0.424807 gen alk 0.453637 leucemia linfoblástica aguda 0.499911 estadio ii 0.457571 siguientes especialistas 0.421884 siguientes tipos 0.435023 rayos x 0.42189 después.ampliar ecografía 0.422758 enlace drugs approved 0.552427 niño ayuda 0.422955 Sudores nocturnos 0.425131 ondas sonoras 0.421599 células t 0.997508 efectos tardíos 0.61792 PDQ Efectos tardíos 0.432774 líquido cefalorraquídeo 0.752047	sección linfoma 0.486518 Linfoma folicular tipo 0.701733 linfocitos b 0.461134 La terapia 0.636115 encontrarlo.ampliar exploración 0.423664 determinados cambios 0.538253 PDQ Tratamiento 0.508964 líquido incoloro 0.436562 explorador tep 0.424899 siguientes factores 0.424861 sistema nervioso central 0.543338 proteína llamada cinasa 0.449366 mayores probabilidades 0.423685 Non-Hodgkin Lymphoma 0.486305 estadio i 0.458742 tipo paniculitis 0.446711 Estados Unidos 0.425103 estadio iii 0.456847 tejido linfoide 0.449965 ósea fabrica glóbulos 0.477114 almacena glóbulos 0.436048 células b 0.553761 Hodgkin infantil recidivante 0.525837	CLICK HERE
1952	National Cancer Institute	Html	es	Tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple).	siguientes procedimientos 0.346148 células madre 0.945416 causa signos 0.305542 trasplante autógeno 0.329369 suficientes glóbulos 0.313511 siguientes cambios 0.312466 suficientes células 0.367406 células madre formadoras 0.329864 siguientes tipos 0.318034 siguientes fases 0.308352 rayos x 0.307538 causa hipercalcemia 0.310068 sumario tratamiento 0.33895 células anormales.ampliar aspiración 0.361154 causa problemas 0.309382 Nuevas combinaciones 0.305801 lesiones óseas 0.305545 National Cancer Institute 0.305225 siguientes riesgos 0.305748 células plasmáticas.Gammapatía 0.37332	Multiple Myeloma 0.338693 Instituto Nacional 0.318628 Plasma Cell Neoplasms 0.366703 PDQ Tratamiento 0.31456 presente sección 0.305256 beta-2 microglobulina 0.490964 Drugs Approved 0.337847 siguientes signos 0.334405 estudio regímenes 0.30494 Physician Data Query 0.319252 estadio iii 0.3425 proteína m 0.36173 inhibidor hdac 0.307303 siguientes enlaces 0.307028 células sanguíneas maduras 0.372655 células b 0.368037 siguientes pruebas 0.314313 siguientes sumarios 0.313298 Other Plasma Cell 0.367102	CLICK HERE
2077	National Cancer Institute	Html	es	Pruebas genéticas para síndromes hereditarios de cáncer	Trata de pruebas genéticas para riesgos heredados de cáncer; incluye tipos de pruebas, para quién son, explicación y confidencialidad de los resultados. Ofrece información de pruebas genéticas a domicilio o pruebas para el consumidor.	paciente grupos 0.426785 ningún efecto 0.430963 direct-to-consumer genetic testing 0.524243 Clinical Chemistry 0.427805 Privacy Rule 0.424134 Accountability Act 0.423749 gen mutante 0.448711 Clinical Laboratory Improvement 0.443406 copia mutante 0.438081 seguro médico 0.523691 valiosa oportunidad 0.42438 gen alteraciones 0.444199 Topol E 0.422575 profesionales genéticos 0.423689 información genética 0.694265 PubMed Abstract 0.469151 PMC Article 0.422751 pruebas genéticas caseras 0.933419 Clinical Oncology 0.46864 reliable or risky 0.440953 GWAS) por medio 0.422097 pequeña porción 0.422164 hijo hereda 0.4346 leyes gina 0.4236 determinada persona 0.471237	profesional conocedor 0.425068 negativo carente 0.503682 Health Information Portability 0.441872 cuidado preventivo 0.422328 Clinical Oncology Policy 0.44516 ASHG statement 0.425726 genomic testing 0.424164 conocida mutación 0.495717 falsa seguridad 0.422355 Genética Humana 0.494712 Javitt G 0.4224 Federal Trade Commission 0.438077 Human Genetics 0.422666 cabo pruebas 0.510628 antecedentes familiares 0.466262 pruebas quizás 0.52233 posibles alternativas 0.424779 complicada decisión 0.427954 estudios por asociación 0.422415 profesional genético 0.434126 negativo falso 0.497922 hijos hombres 0.425049 llama portadores 0.430487 llamadas polimorfismos 0.425347	CLICK HERE